Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers

Research output: Contribution to journalJournal articleResearchpeer-review

  • Stine N. Nielsen
  • Eriksson, Frank
  • Susanne Rosthoej
  • Mette K. Andersen
  • Erik Forestier
  • Henrik Hasle
  • Lisa L. Hjalgrim
  • Ann Aasberg
  • Jonas Abrahamsson
  • Mats Heyman
  • Ólafur G. Jónsson
  • Kaie Pruunsild
  • Goda E. Vaitkeviciené
  • Kim Vettenranta
  • Schmiegelow, K.

BACKGROUND: The improved survival rates for childhood acute lymphoblastic leukemia (ALL) may be jeopardized by the development of a second cancer, which has been associated with thiopurine therapy.

PROCEDURE: We retrospectively analyzed three sequential Nordic Society of Paediatric Haematology and Oncology's protocols characterized by increasing intensity of thiopurine-based maintenance therapy. We explored the risk of second cancer in relation to protocols, risk group, thiopurine methyltransferase (TPMT) activity, ALL high hyperdiploidy (HeH), and t(12;21)[ETV6/RUNX1].

RESULTS: After median 9.5 years (interquartile range, 5.4-15.3 yrs) of follow-up, 40 of 3,591 patients had developed a second cancer, of whom 38 had non-high-risk B-cell precursor ALL. Patients with standard-risk ALL, who received the longest maintenance therapy, had the highest adjusted hazard of second cancer (hazard ratio [HR], intermediate vs. standard risk: 0.16, 95% CI: 0.06-0.43, P < 0.001; HR, high vs. standard risk: 0.09, 95% CI: 0.02-0.49, P = 0.006); no significant effects of protocol, age, or white blood cell count at diagnosis, ALL HeH, or t(12;21)[ETV6/RUNX1] were observed. A subset analysis on the patients with standard-risk ALL did not show an increased hazard of second cancer from either HeH or t(12;21) (adjusted HR 2.02, 95% CI: 0.69-5.96, P = 0.20). The effect of low TPMT low activity was explored in patients reaching maintenance therapy in clinical remission (n = 3,368); no association with second cancer was observed (adjusted HR 1.43, 95% CI: 0.54-3.76, P = 0.47).

CONCLUSIONS: The rate of second cancer was generally highest in patients with low-risk ALL, but we could not identify a subset at higher risk than others.

Original languageEnglish
Article numbere26518
JournalPediatric Blood & Cancer
Volume64
Issue number10
Pages (from-to)1-9
Number of pages9
ISSN1545-5009
DOIs
Publication statusPublished - Oct 2017

    Research areas

  • Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Chromosomes, Human, Pair 12, Chromosomes, Human, Pair 21, Female, Follow-Up Studies, Humans, Male, Methyltransferases, Neoplasms, Second Primary, Ploidies, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Risk Factors, Translocation, Genetic, Journal Article

ID: 184633904